Pmh60 a Pharmacoeconomic Comparison of Escitalopram and Duloxetine in Treatment of Major Depressive Disorder (Mdd) in the United Kingdom

Wade, AG; Fernández, J.R. López; François, C.; Hansen, Karen; Despiegel, Nicolas; Danchenko, Natalya

doi:10.1016/s1098-3015(10)65110-8

Value in Health

2007

DOI: 10.1016/s1098-3015(10)65110-8

|View full text |Cite

Pmh60 a Pharmacoeconomic Comparison of Escitalopram and Duloxetine in Treatment of Major Depressive Disorder (Mdd) in the United Kingdom

AG Wade¹,

J.R. López Fernández²,

C. François³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2007

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders

Lam¹,

Annemans

2007

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

In addition to the large personal challenge that depression and anxiety present, these disorders are associated with a substantial burden of disability and lost productivity, and are responsible for considerable strain on healthcare resources and on society. Escitalopram is recommended as first-line therapy for the treatment of major depressive disorder and severe depression, and is indicated in anxiety disorders. Compared with other antidepressants, escitalopram has equal or superior efficacy, as proven in clinical trial settings, equal or superior real-life effectiveness, established in both clinical and observational studies, and a better tolerability profile. While drug acquisition costs are higher for escitalopram than for generic drugs such as fluoxetine and citalopram, numerous prospective and modeled economic analyses show that associated direct and indirect costs of treatment are lower with escitalopram than with citalopram, fluoxetine, sertraline and venlafaxine. Thus, escitalopram appears to be more economically efficient than many antidepressants currently available. Escitalopram has a prominent role in the treatment of major depressive disorder and anxiety disorders, and may also prove to be important in the treatment of mixed depressive anxiety disorder.

show abstract

Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders

Lam¹,

Annemans

2007

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Pmh60 a Pharmacoeconomic Comparison of Escitalopram and Duloxetine in Treatment of Major Depressive Disorder (Mdd) in the United Kingdom

Cited by 1 publication

References 0 publications

Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders

Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders

Contact Info

Product

Resources

About